RINVOQ ER 30 MG TABLET

Upadacitinib
$228.8250per EA

Strength

30 mg/1

Manufacturer

AbbVie Inc.

NDC

00074231030

Classification

Brand

Dosage Form

TABLET, EXTENDED RELEASE

Route

ORAL

Last Updated

1/2/2026

Active Ingredients

UPADACITINIB

Approval Type

New Drug (NDA)

FDA Application

NDA211675

On Market Since

8/16/2019

Pharmacological Classes

Janus Kinase Inhibitor
Janus Kinase Inhibitors

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

+4.8%

1Y

+5.2%

3Y

N/A

5Y

N/A

All

+10.6%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.